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BACKGROUND: CYT997 is a novel microtubule inhibitor and vascular-disrupting agent with marked preclinical anti-tumour activity.
METHODS: This phase I dose-escalation study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of CYT997
administered by continuous intravenous infusion over 24h every 3 weeks to patients with advanced solid tumours.
RESULTS: Thirty-one patients received CYT997 over 12 dose levels (7–358mgm
 2). Doses up to 202mgm
 2 were well tolerated.
Dose-limiting toxicities were observed at 269 and 358mgm
 2, consisting of grade 3 prolonged corrected QT interval in two patients
and grade 3 hypoxia and grade 4 dyspnea in one patient. All toxicities were reversible. The pharmacokinetics of CYT997 were linear
over the entire dose range. Dynamic contrast-enhanced magnetic resonance imaging scans showed significant changes in tumour
K
trans values consistent with vascular disruption in 7 out of 11 evaluable patients treated at CYT997 doses of X65mgm
 2.
Moreover, plasma levels of von Willebrand factor and caspase-cleaved cytokeratin-18 increased post-treatment at higher dose levels.
Among 22 patients evaluable for response, 18 achieved stable disease for 42 cycles.
CONCLUSIONS: CYT997 was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption
in tumours.
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The ability of solid tumours to promote a pathological neovascu-
lature is essential to their survival, growth and metastasis.
Therefore, agents that damage or inhibit the formation of tumour
blood vessels have the potential for significant anti-cancer activity
(Folkman, 2002). It is critical that these interventions selectively
target tumour blood vessels so that vascular toxicity to normal
tissues is limited. Encouragingly, there are major biological
differences between the immature disorganised microvasculature
of malignant tumours and normal microvessel networks, and these
differences provide the basis for therapeutic selectivity (Hinnen
and Eskens, 2007).
One class of vascular-targeting anti-cancer agents is the vascular-
disrupting agents (VDAs). These drugs selectively disrupt endothe-
lial cells within the tumour microvasculature, resulting in rapid
shutdown of tumour blood flow (Hinnen and Eskens, 2007; Tozer
et al, 2008). In animal models, this typically results in necrosis of the
central region of the tumour, with a thin peripheral rim of surviving
tumour cells that are presumably supplied by vessels in the adjacent
normal tissue. Agents in this class include combretastatin A4
phosphate, 5,6-dimethylxanthenone-4-acetic acid, ZD6126 and
others (Rustin et al, 2003; Stevenson et al, 2003; Beerepoot et al,
2006; McKeage et al, 2006). Although different mechanisms of
action are operative, some VDA are tubulin-interactive small
molecules that selectively inhibit microtubule polymerisation in
endothelial cells (Tozer et al, 2008; Schwartz, 2009). Tumour
endothelium is dependent on its microtubule cytoskeleton for
structural and functional integrity, and disruption of microtubules
can trigger a series of changes that shutdown blood flow in the
tumour microvasculature (Hinnen and Eskens, 2007). Several VDA
are currently in clinical development and some have shown clinical
anti-cancer efficacy (Dowlati et al, 2002; McKeage et al, 2008).
CYT997 is a synthetic small molecule that inhibits tubulin
polymerisation, disrupts cellular microtubules and demonstrates
potent cytotoxic activity against tumour cell lines in vitro (Burns
et al, 2009b). It also showed significant vascular-disrupting activity
in preclinical tumour models (Burns et al, 2009a). CYT997 is orally
bioavailable and repeat-dose animal toxicology studies have
evaluated both intravenous (i.v.) and oral schedules. Common
toxicities included hypocellularity of spleen, thymus and bone
marrow, leucopenia and mucosal hemorrhage and ulceration in
the gastrointestinal tract. Mild bradycardia was observed at higher
doses, but there were no other cardiovascular or neurological
toxicities (Cytopia Research Pty Ltd, 2009).
We now report the results of a phase I dose-finding study of
CYT997 administered by continuous 24-h i.v. infusion in patients Revised 28 May 2010; accepted 12 July 2010
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swith refractory advanced cancer. Pharmacodynamic (PD) evalua-
tions of vascular-disrupting activity were performed, including
measurement of plasma von Willebrand factor (vWF) and
circulating endothelial cells (CECs), and assessment of the tumour
microvasculature with dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI). We also evaluated plasma levels
of caspase-cleaved cytokeratin-18 (CK-18) as a surrogate marker
of tumour apoptosis.
PATIENTS AND METHODS
Patients were recruited and followed up at Royal Brisbane and
Women’s Hospital, and CYT997 infusions were administered in
the Q-Pharm phase I unit (Q-Pharm Pty Ltd, Herston, Queensland,
Australia). The study was approved by the human research ethics
committees of both institutions. All patients gave written informed
consent.
Patient eligibility
Eligible patients were at least 18 years old with a histologically
confirmed solid malignant tumour that was refractory to standard
treatment or had no available standard therapy. An Eastern
Cooperative Oncology Group performance status of p2 and a life
expectancy of 43 months were required. Adequate bone marrow,
renal and hepatic function for study entry was defined as absolute
neutrophil count X1.5 10
9 per litre, platelet count X100 10
9
per litre, creatinine p1.5  upper limit of normal, total bilirubin
p1.5  upper limit of normal and aspartate aminotransferase
and alanine aminotransferase p3  upper limit of normal (p5 
upper limit of normal if liver metastases). A normal left ventricular
ejection fraction on a gated heart pool scan or echocardiogram was
required. Patients had received no anti-cancer chemotherapy or
hormonal therapy in the past 4 weeks (6 weeks if the last regimen
included mitomycin-C or nitrosoureas). Female patients of
child-bearing potential were required to have a negative serum
pregnancy test.
Patients were excluded from the study if they had a history of
myocardial infarction or stroke within the past 6 months, unstable
angina pectoris or acute ischaemic changes on an electrocardio-
gram (ECG), a history of diabetic retinopathy, symptomatic
peripheral arterial disease or major surgery in the past 30 days.
Patients with uncontrolled diarrhea despite optimal medication or
any history of acute gastrointestinal bleeding were also excluded.
Other exclusion criteria were coexisting illness likely to interfere
with trial procedures, known brain metastases and known human
immunodeficiency virus infection.
CYT997 administration
CYT997 was supplied by Cytopia Research in vials containing
100mg of study drug. On the day of dosing, CYT997 was dissolved
in sterile normal saline (50ml per vial) and filtered twice through a
0.22-mm polyethersulfone filter (Millex GP, Millipore, Billerica,
MA, USA). The required dose was added to a 500-ml bag of sterile
normal saline and administered by continuous i.v. infusion over
24h. Doses were repeated every 21 days. Because of grade 2 i.v.-site
reactions involving peripheral cannula sites at 23 and 35mgm
 2,
higher doses were administered via a central venous access device.
Dose escalation
The starting dose of CYT997 was 7mgm
 2, which was approxi-
mately one tenth of the severely toxic dose in rats. Doses were
escalated according to a modified Fibonacci series. Initially, three
patients were entered per dose level (standard dose-escalation
phase). As no drug-related toxicity of 4grade 2 had been observed
by the completion of dose-level 6 (65mgm
 2), an accelerated
dose-escalation scheme was adopted (Simon et al, 1997). This
required enrolment of one patient per dose level until the
occurrence of either dose-limiting toxicity (DLT) (see below) in
one patient or first-cycle grade 2 drug-related toxicity in two or
more patients. At that point, standard dose escalation was to be
resumed.
Toxicities were graded according to the Common Terminology
Criteria for Adverse Events of the National Cancer Institute
(version 3.0). Dose-limiting toxicity was based on toxicities during
the first cycle of CYT997 and was defined as grade 4 neutropenia
lasting X5 days, associated with fever (X38.51C) or requiring
antibiotics; grade 4 thrombocytopenia (grade 3 if bleeding); or
drug-related non-haematological toxicity Xgrade 3 (excluding
nausea, vomiting and diarrhoea, unless receiving optimal suppor-
tive care). In the absence of DLT, escalation proceeded to the next
dose level. However, if a DLT was observed, then the dose level was
expanded to a planned total of 6 patients. The maximum tolerated
dose (MTD) was defined as the dose that resulted in X2 out of
6 patients developing a DLT. Intrapatient dose escalation was
permitted in both the standard and accelerated escalation parts of
the study, but required that the dose level immediately above had
been completed without the occurrence of DLT.
Patient assessments
Pretreatment evaluation included a medical history and physical
examination, assessment of performance status, 12-lead ECG,
urinalysis and laboratory studies (including full blood count,
coagulation profile, electrolytes, urea, creatinine, liver function
tests, glucose, uric acid, calcium and phosphate). Patients were
admitted to the Q-Pharm inpatient facility for 48h with their first
CYT997 infusion and for 24h with subsequent doses. Continuous
cardiac monitoring by telemetry, continuous pulse oximetry and
frequent vital sign assessments were performed during admissions.
For the first CYT997 cycle, laboratory studies and a 12-lead ECG
were repeated at 8, 24 and 48h from starting the infusion and then
weekly. For subsequent cycles, laboratory studies and an ECG were
performed prior to and at completion of the CYT997 infusion, and
laboratory studies were performed weekly. With the demonstra-
tion of CYT997-induced prolongation of the corrected QT (QTc)
interval at higher doses, the frequency of 12-lead ECG tracings was
increased to every 6h during the first infusion and until 12h after
its completion. Assessment of left ventricular ejection fraction by
gated heart pool scan or echocardiogram, and pulmonary function
by spirometry and measurement of lung volumes and diffusing
capacity, was performed at baseline and after every 2 cycles of
CYT997. Radiological evaluation of tumours was performed at
baseline and then after every 2 cycles. Efficacy in patients with
measurable disease was assessed using Response Evaluation
Criteria in Solid Tumors (RECIST) (Eisenhauer et al, 2009).
Patients were considered evaluable for response if they had at least
one measurable tumour lesion at baseline that was reevaluated
with the same imaging modality after 2 cycles of study treatment.
Pharmacokinetic studies
Concentrations of CYT997 in plasma and urine were determined
for the first dose of study drug in each patient. Blood samples were
drawn immediately prior to starting the infusion and then at 4, 8,
12, 16, 20 and 24h from the start of infusion, and at 10, 20 and
40min and 1, 1.5, 2, 4, 6, 8, 12, 24 and 48h after completion of the
infusion. Each sample consisted of B5ml of blood collected in an
EDTA-coated tube. Samples were centrifuged at 1300g for 10min
at room temperature within 30min of collection. Plasma was then
transferred to a fresh tube and stored at  801C, pending analysis.
Urine was collected for a 24-h period prior to starting the first
CYT997 infusion and a second 24-h period beginning with infusion
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scommencement. Urine volumes were measured and an aliquot was
stored at  801C for analysis.
Analysis of plasma and urine was conducted using validated high
performance liquid chromatography–mass spectrometry methods.
The area under the concentration of CYT997 in plasma vs time curve
from the start of the infusion until the last quantifiable concentration
(AUC0 t) was calculated by the linear trapezoidal method using
WinNonlin (Version 5.1, Pharsight Corporation, Mountain View,
CA, USA). The area beyond the last quantifiable concentration to
infinity (AUCt N) was calculated by extrapolation using the
terminal rate constant (Kel); the latter calculated from at least three
data points of the terminal phase. The two areas were summed to
give AUCo N. Terminal half-life (t1
2) was the quotient of 0.693 and
Kel. Clearance was calculated as the quotient of the entire i.v. dose
infused and AUC0 t (CL) and as the quotient of the rate of infusion
and the mean of the concentrations at 16 and 20h (CLss)w h e ns t e a d y
state was assumed.
Pharmacodynamic studies
Plasma vWF antigen Blood samples in citrate tubes were
centrifuged twice and the plasma was stored at  701C for assay
in batches. The vWF antigen levels in the plasma were determined
with the vWF:Ag LIATest immunoturbidometric assay, according
to the manufacturer’s instructions (Diagnostica-Stago, Asnie `res-
sur-Seine, France). Samples were read using a Stago coagulation
analyser. The vWF levels were obtained at baseline and again at 8,
24 and 48h after the start of the first CYT997 infusion.
Circulating endothelial cells Heparinised peripheral blood
samples were centrifuged at 200g for 10min at room temperature,
and the plasma was removed and stored at  701C for the M30
Apoptosense ELISA assay (see below). The remaining blood cells
were resuspended in RPMI 1640, layered over Ficoll-Paque PLUS
(GE Healthcare, Little Chalfont, Buckinghamshire, UK) and
centrifuged at 970g for 10min at room temperature with the
brake off. The mononuclear cell layer was then collected and
washed three times in PBS, prior to staining with monoclonal
mouse anti-human CD146-PE, CD31-FITC and CD45-APC anti-
bodies (BD Pharmingen, San Diego, CA, USA). Non-viable cells
were stained with 7-amino-actinomycin D (7-AAD, BD Pharmingen).
A Becton Dickinson (San Jose, CA, USA) FACSCalibur flow
cytometer was used to enumerate CEC as CD146þ/CD31þ/
CD45  cells, as previously described (Bertolini et al, 2006). Assays
were performed at baseline and again at 24 and 48h, and 6 days,
from starting the first CYT997 infusion.
Plasma CK-18 fragment assay The M30 Apoptosense ELISA assay
(Peviva AB, Bromma, Sweden) was used according to the
manufacturer’s instructions to assay for caspase-cleaved CK-18
fragments in plasma samples isolated during the CEC assay (see
above). Each sample was assayed in duplicate. Absorbance was
read at 450nm by a Versamax tunable microplate reader
(Molecular Devices, Sunnyvale, CA, USA). The CK-18 fragment
assays were performed at baseline and again at 24 and 48h, and 6
days, from starting the first CYT997 infusion.
DCE-MRI scans Two baseline DCE-MRI scans were performed in
the week prior to commencing study treatment to evaluate
reproducibility of permeability measures and post-treatment scans
were performed at 26h and 6 days from starting the first CYT997
infusion. Imaging was performed on a 1.5-T Siemens Avanto
scanner (Erlangen, Germany). After acquisition of a number of
anatomical T2-weighted HASTE images for tumour localisation,
four 3D fast gradient echo images were acquired to enable
calculation of a baseline T1 map for DCE analysis. These images
were acquired using variable flip angles (51,1 0 1,2 0 1 and 251) and a
field of view of 220mm, slice thickness 4mm, acquisition matrix
128 128, repetition time 4.3ms and four averages in an axial
plane. This was followed by a DCE acquisition series at a flip angle
of 201, consisting of 75 scans with a temporal spacing of B3s.
Gadolinium-based contrast agent (Gd-DTPA-BMA; Omniscan,
Amersham Health AS, Oslo, Norway) was injected as a bolus over
4s at a dose of 0.1mmolkg
 1 of body weight. A vascular input
function was measured within a large artery close to the site of the
tumour. A similar anatomical location was used for all data in the
time series. Permeability maps (K
trans) were generated using the
pharmacokinetic modelling method reported by Li et al (2000). All
follow-up anatomical and permeability maps were carefully
registered to the baseline anatomical image acquired at the first
imaging time point using an affine transformation. To identify
regions of interest (ROI) on permeability maps for statistical
analyses of tumour K
trans values, the first image in the DCE series,
acquired without contrast agent, was subtracted from the last
image in the series. This approach enabled delineation of the
tumour margins exhibiting post-contrast enhancement. This
procedure was repeated for both DCE data sets acquired prior to
CYT997 treatment and an averaged ROI generated. The averaged
ROI was then transferred to the registered permeability maps
acquired before and after CYT997 treatment for analysis of K
trans
changes. Results were reported as whole-tumour median K
trans
values, colour-coded K
trans maps and histogram analyses (Watson
et al, 2006). Tumour K
trans maps from all time points were
superimposed on the anatomical images acquired during the first
baseline DCE-MRI scan, as these were acquired at the highest
resolution. For histogram analyses, voxels were grouped in deciles,
with the first decile containing the lowest 10% of K
trans values in
the initial baseline scan, the second decile containing the next
lowest 10% and so on. Considering the voxels in each decile
individually, the differences in K
trans between the first baseline
scan and each of the second baseline, first post-treatment and
second post-treatment scans were calculated. Histograms were
then constructed for each post-treatment time point so that bars
indicated the mean change in K
trans for each decile of voxels.
Statistics Differences between higher-dose and lower-dose
groups with respect to plasma levels of vWF antigen were assessed
for statistical significance using an unpaired two-tailed Student’s
t-test. For the histogram analyses of DCE-MRI results, the statis-
tical significance of post-treatment changes in K
trans in the voxels
of a particular decile was determined by comparison with the
changes in that decile between the first and second baseline scans.
This was achieved using an unpaired Wilcoxon rank-sum test.
RESULTS
Patient characteristics
Thirty-one patients were enrolled in the study between June 2005
and July 2007. The baseline characteristics of these patients are
summarised in Table 1.
Dose escalation and MTD
A total of 98 cycles of CYT997 were administered on study (median
2 cycles per patient, range 1–6) over a total of 12 dose levels
(7–358mgm
 2). Three patients were enrolled per dose level
until completion of dose-level 6 (65mgm
 2). As no drug-related
toxicities of grade 42 had been observed, an accelerated dose-
escalation scheme was substituted and one patient was recruited
per dose level up to and including 202mgm
 2 (Table 2). The first
patient to receive 269mgm
 2 experienced a DLT, consisting of
grade 3 prolongation of the QTc interval. This dose level was
therefore expanded to a total of six patients, without additional
DLT being observed. Recruitment to the 358mgm
 2 dose level
Phase I trial of CYT997
JD Lickliter et al
599
British Journal of Cancer (2010) 103(5), 597–606 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthen proceeded and 2 out of 3 patients at this level experienced
DLT, consisting of grade 3 prolongation of the QTc interval in one
patient and grade 3 hypoxia and grade 4 dyspnea in a second
patient. This defined 358mgm
 2 as the MTD for CYT997 given by
24-h i.v. infusion every 3 weeks.
Safety and tolerability
Treatment-related adverse events of Xgrade 2 are shown in
Table 2, with the exception of occurrences of grade 2 peripheral
i.v.-site reactions that were observed in one patient at each of
CYT997 doses of 23 and 35mgm
 2. These reactions involved
localised induration and inflammation at peripheral i.v. adminis-
tration sites, which began within 24h of completing the CYT997
infusion and subsided over several days. A protocol amendment
mandated that subsequent dose levels be administered via a central
venous access device and no further treatment-related local venous
toxicity was observed.
Haematological toxicity CYT997 had no effect on blood counts in
most patients. However, one heavily pretreated patient with ovarian
cancer who received 269mgm
 2 developed grade 3 neutropenia in
cycles 1–3 and lesser grades of neutropenia in cycles 4–6. On each
occasion, the neutrophil count reached its nadir and recovered to
normal within 24h of completing the CYT997 infusion. There were
no episodes of neutropenic fever. The same patient also developed
transient grade 1 thrombocytopenia, grade 2 central abdominal
cramps and grade 1 diarrhea with a similar time course to the
neutropenia. It may be noteworthy that they had previously received
abdominal radiation. Another patient developed grade 3 anaemia
after receiving CYT997 at 358mgm
 2.N oc h a n g e si nt h e
prothrombin time, activated partial thromboplastin time or plasma
fibrinogen level were observed at any dose level.
Prolonged QTc interval One patient at each of CYT997 doses of
269 and 358mgm
 2 developed grade 3 prolongation of the QTc
interval, with the maximum QTc interval observed reaching
518ms. The patient treated at 269mgm
 2 had a right bundle
branch block and grade 1 prolongation of the QTc interval at
baseline, whereas the patient treated at 358mgm
 2 had a normal
baseline QTc interval. In both patients, the QTc-interval prolonga-
tion reduced to pgrade 1 within 8h of completing the CYT997
infusion. Grade 2 prolonged QTc interval was seen in a second
patient at 358mgm
 2, which followed early stopping of the first
CYT997 infusion because of dyspnea and hypoxia (see below). No
ventricular arrhythmias were associated with prolongation of the
QTc interval during this study.
Other non-haematological toxicities Three additional patients
developed grade 3–4 non-haematological toxicities. The first of
Table 2 Toxicity of CYT997
Dose level 49mgm
 2 65mgm
 2 86mgm
 2 114mgm
 2 152mgm
 2 202mgm
 2 269mgm
 2 358mgm
 2
No. of patients 331 1 1 1 6 3
Toxicity grade 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4
Haematological
Neutropenia                     1      
Lymphopenia                     1      
Anaemia                          1  
Non-haematological
Prolonged corrected QT interval                    1*   11 * 
Hypertension                    1      
Nausea                 1         
Pain – abdomen    1               1      
Pain – chest/thorax                     1      
Dyspnea                          1*
Hypoxia                         1*  
Headache    1                     
Visual disturbance                       1    
Fever                        1   
Elevated creatinine           1               
Proteinuria                        1   
Number of patients with adverse events of grade X2 that were possibly, probably or definitely related to CYT997 are shown. Several episodes of the same toxicity in the
one patient are scored as one event and only the worst grade is shown. Multiple different toxicities occurring simultaneously in the one patient are scored as separate toxicities.
The highest eight dose levels are shown (dose levels 5–12). Dose-limiting toxicities are asterisked.
Table 1 Patient characteristics
Characteristic No. of patients
Total patients 31
Age (years)
Median 57
Range 21–75
Sex
Male 15
Female 16
ECOG performance status
08
11 4
29
Tumour type
Melanoma 5
Mesothelioma 5
Renal cell 4
Breast 2
Prostate 2
Colorectal 2
Head and neck 2
Other 9
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
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sthese patients had a pleural mesothelioma and was treated at
269mgm
 2. They experienced grade 3 chest pain on day 4 of their
third cycle of CYT997. This had the clinical features of tumour pain
and took 5 days to decrease in severity to ograde 2. Similar pain of
maximum grade 2 severity occurred in the same patient during
other cycles. The second patient developed transient uniocular
visual loss on day 4 of their second CYT997 cycle, which was dosed
at 269mgm
 2. This resolved after 1min without sequelae.
Subsequent examination of the optic fundus was normal and a
carotid doppler study revealed no significant stenoses. This event
did not affect dose escalation because it occurred during the second
cycle. However, the first CYT997 infusion in this patient was
stopped early after 17h because of a thrombosis related to their
peripherally inserted central catheter, and the second dose was the
first given at the allocated dose level. No further doses were given to
this patient. The third patient had a history of radiation to a lung
mass and received CYT997 at 358mgm
 2. They developed grade 3
hypoxia and grade 4 dyspnea during infusion of study drug, which
was ceased early after 15h. The clinical status then significantly
improved and the hypoxia resolved over the next several hours.
A 12-lead ECG showed sinus tachycardia and no other acute
changes. Chest X-ray revealed some increase in a pre-existing
unilateral pleural effusion (from mild to moderate) and subtle
bilateral interstitial lung opacities that had cleared on a repeat film
the next day. Routine haematology and biochemistry studies were
unrevealing apart from a transient grade 2 elevation of plasma
lactate dehydrogenase. No further CYT997 was given to this patient.
Several grade 2 non-haematological toxicities were observed in
one to two patients each, including hypertension, elevated
creatinine, proteinuria, nausea, abdominal pain, headache and fever
(Table 2). Of note, patient 19 developed grade 2 elevation in plasma
creatinine after their dose was escalated from 86 to 114mgm
 2. This
patient had previously undergone a nephrectomy for renal cell
carcinoma and had grade 1 elevated creatinine and microhaematuria
at baseline. The plasma creatinine level increased from 119mmoll
 1
at baseline to 174mmoll
 1 at 8h into the CYT997 infusion. Study
drug infusion was ceased immediately, and the creatinine returned
to baseline levels within 2 days. No nephrotoxicity was observed in
any other patient. All toxicities were reversible. In contrast to most
other microtubule-targeting anti-cancer agents, CYT997 was not
associated with the development of peripheral neuropathy.
Pharmacokinetics
Pharmacokinetic data summarised by dose level are provided in
Table 3. For five subjects, it was not possible to calculate a terminal
rate constant and, therefore, AUC0 N. However, the extrapolated
area from the 23 subjects in which it was possible to calculate the rate
constant represented no more than 2.6% of the total area. Therefore,
AUC0 t was used for the calculation of CL in all subjects. There was a
highly significant linear relationship between AUC0 t and the total
dose of CYT997 infused (Po0.001; Figure 1A), indicating that the
pharmacokinetics of CYT997 were linear over the entire 50-fold dose
range investigated in this study (7–358mgm
 2). The plasma
concentrations of CYT997 at steady state (Css,T a b l e3 )w e r et h e
maximum concentrations achieved during the infusions. Similar to
the AUC0 t, Css increased in a dose-proportional manner across the
entire dose range (Figure 1B). Individual values for CL extended
from 0.59 to 1.56lh
 1kg
 1, with the values for CL calculated from
AUC0 t being, on average, about 10% less than the values calculated
from the concentrations at steady state. A small percentage (o0.7%)
of the i.v. dose was excreted unchanged in urine, suggesting extensive
hepatic clearance. The values for the apparent volume of distri-
bution (mean 6.5lkg
 1; range 2.6–10.6lkg
 1) suggest moderate-to-
extensive distribution beyond the central compartment. Plasma
concentration data indicate a bi-exponential decline in CYT997 levels
following cessation of the 24-h infusion (Figure 1C). The mean
terminal elimination half-life was 4.4h (range 1.7–7.5h).
Pharmacodynamic studies
Plasma vWF levels Von Willebrand factor is present in high
concentrations in endothelial cells and plasma levels of vWF
antigen increase following endothelial cell injury (Lee et al, 2005).
Plasma vWF antigen was therefore used in the current study as a
surrogate marker of endothelial damage because of vascular-
disrupting activity. Adequate baseline and post-treatment data
were available on 26 patients, but two were excluded due to an
unexplained borderline-low vWF antigen level at baseline or the
occurrence of a line-related thrombosis during CYT997 infusion.
Figure 2A shows that plasma vWF antigen increased at 24h after
commencing CYT997 in patients receiving doses of X202mgm
 2.
At this time point, the mean (±s.d.) vWF level was 136% (±23%)
of baseline for doses X202mgm
 2, which was significantly
elevated (Po0.001) when compared with the mean level of
patients receiving o202mgm
 2. Levels in the higher-dose group
declined to 123% (±25%) of baseline by 48h, but were still
significantly higher (Po0.05) than those in lower-dose patients.
Circulating endothelial cells CEC were measured in the peri-
pheral blood of 17 patients as CD146þ/CD31þ/CD45  cells. The
14 patients with evaluable data received CYT997 at doses ranging
Table 3 Pharmacokinetics of CYT997
Dose (mgm
 2) No. of patients Css (ngml
 1)
a AUC0 t (nghml
 1)
a Terminal t1
2 (h)
a CL (lh
 1kg
 1)
a Vapp (lkg
 1)
a
7 3 8.5 (4.4) 178 (68) 2.8 (0.6) 0.89 (0.23) 3.5 (1.0)
14
b 3 15.5 (4.9) 312 (58) 6.6 (1.2) 0.93 (0.20) 7.8 (1.4)
23 3 22.0 (8.5) 470 (153) 4.3 (1.2) 1.09 (0.39) 6.3 (0.8)
35
b 3 31.2 (9.2) 782 (221) NE 1.04 (0.26) NE
49
b 3 33.5 (3.2) 1030 (480) 3.4 (2.4) 1.16 (0.50) 4.1 (0.4)
65 3 67.8 (17.4) 1370 (280) 4.2 (1.1) 1.05 (0.26) 6.1 (0.3)
86 1 77.3 1780 5.4 1.07 8.3
114 1 135 2920 4.6 0.85 5.7
152 1 110 2140 3.9 1.50 8.4
202 1 154 3630 4.5 1.36 8.7
269 5
c 217 (57) 4570 (1130) 5.1 (1.7) 1.11 (0.23) 8.2 (3.0)
358 2
c 345 (69) 5640 (2910) 4.6 (2.3) 0.99 (0.18) 6.8 (4.6)
Abbreviations: Css¼concentration at steady state; AUC0 t¼area under the CYT997 plasma concentration vs time curve from the start of the infusion until the last quantifiable
concentration; CL¼clearance; Vapp¼apparent volume of distribution; NE, not evaluable.
aPharmacokinetic parameters represent the mean (s.d.) for the corresponding dose
level.
bThe concentrations in plasma profile for one subject at 14mgm
 2, all three at 35mgm
 2 and one at 49mgm
 2 could not be extrapolated to infinity and, therefore, the
number of subjects available for calculation of mean terminal t1
2 was reduced accordingly.
cData were not available on one patient in each of the 269 and 358mgm
 2 dose levels
because of early termination of CYT997 infusions.
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sfrom 49 to 358mgm
 2. Post-treatment increases in CEC were seen
in only one patient (patient 29), who was treated at the highest
dose level. In this case, CEC were essentially undetectable at
baseline (o0.01% of MNC) and then increased to 0.09% and 0.30%
of MNC at 48h and 6 days, respectively, after commencing
CYT997. The CEC detected at these latter time points stained
positively with 7-AAD, indicating that they were non-viable.
Caspase-dependent CK-18 fragments Plasma levels of caspase-
cleaved CK-18 measured with the M30 ELISA assay have been used
to quantify apoptosis induced in epithelial cancers by chemo-
therapy or other treatments (de Haas et al, 2008). Seventeen
patients in the current study were evaluable for the analysis
of caspase-cleaved CK-18 levels, which were observed to increase
at 24h after commencing CYT997 in a dose-dependent manner
(Figure 2B). The majority of patients showing increases had
epithelial carcinomas or mesothelioma, which typically express
CK-18 (Moch et al, 1993). One patient with metastatic vaginal
leiomyosarcoma also had a significant post-treatment rise in M30
epitope, although it is notable that this sarcoma subtype expresses
CK-18 in 30% of cases (Chu and Weiss, 2002).
DCE-MRI Fifteen patients underwent DCE-MRI scans before
and after their first CYT997 infusion and, of these, 11 patients
had evaluable DCE-MRI data. Results on four patients were
not evaluable because of excessive patient motion during scanning.
All evaluable patients received CYT997 doses of X65mgm
 2, and
therefore 11 out of 16 patients treated at doses from 65 to
358mgm
 2 were analysed. Whole-tumour median K
trans values at
baseline and both post-treatment time points are shown in Table 4.
The K
trans values significantly decreased in five patients (18, 20, 21,
25 and 26), which is consistent with a reduction in tumour blood
flow in response to study drug in these individuals (Galbraith et al,
2003). In two other patients (19 and 30), there was a significant
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Figure 1 Pharmacokinetic profile of CYT997 given by continuous 24-h
i.v. infusion. (A) Area under the plasma concentration–time curve
(AUC0 t), and (B) plasma concentration at steady state (Css), vs
CYT997 dose level. (C) Mean plasma concentration of CYT997 plotted
against time from the infusion start for the 269mgm
 2 dose level (n¼4);
error bars indicate s.d.
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Figure 2 Vertical scatter plots of (A) von Willebrand factor (vWF)
antigen levels and (B) caspase-cleaved cytokeratin-18 (CK-18) levels in
plasma at 24h after commencing the initial CYT997 infusion, grouped by
CYT997 dose level. Values are expressed as a percentage of baseline values
for each patient and mean values for each dose level are indicated by
horizontal bars. For caspase-cleaved CK-18 levels, each data point
represents the mean of duplicate assays. Note that there was only one
patient per dose level at four of the dose levels (86, 114, 152 and
202mgm
 2).
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spost-treatment increase in tumour K
trans. Maximal response in
tumour K
trans occurred at 26h after starting the CYT997 infusion
in patient 25, whereas in all other cases maximal responses were at
6 days. DCE-MRI results were also subjected to histogram analysis.
Post-treatment time points where the majority of histogram deciles
revealed a statistically significant change in K
trans (Po0.05 for
individual deciles) occurring in the same direction as the change in
the whole-tumour median K
trans value are flagged with bold type in
Table 4. Importantly, there is a close match between time points
showing substantial changes in whole-tumour median K
trans and
those identified by histogram analysis as revealing statistically
significant K
trans changes.
Figure 3 shows K
trans maps for two of the patients who
developed reductions in tumour K
trans following CYT997 treat-
ment. Images from patient 20 show a liver metastasis of non-small
cell lung cancer, with a vascularised rim and presumably necrotic
interior at baseline. Six days following CYT997 administration, a
major reduction in K
trans in the tumour rim was observed,
consistent with marked reduction in tumour perfusion. Similarly,
the K
trans maps from patient 26 indicate marked and widespread
reduction in perfusion of an ovarian carcinoma metastasis at
6 days following CYT997 administration. Histogram analyses
were confirmatory in both patients, with statistically significant
decreases in tumour K
trans seen in most or all deciles at 6 days
post-treatment (Figure 3E and F). Interestingly, the deciles of
voxels with greatest baseline K
trans values (at right in the histo-
grams) were associated with the greatest fall in K
trans following
CYT997 treatment. A similar pattern was observed in other
patients showing significant CYT997-induced changes in tumour
K
trans (data not shown).
As noted above, all patients with evaluable DCE-MRI data
received CYT997 doses between 65 and 358mgm
 2. Within this
dose range, no clear relationship was observed between CYT997
dose level and the likelihood or magnitude of changes in tumour
K
trans. Baseline whole-tumour median K
trans values, however, were
correlated (r¼ 0.84) with the extent of K
trans reduction observed
post-treatment (Figure 4). A correlation persisted (r¼ 0.58)
when the outlying patient with the highest baseline K
trans and
greatest K
trans fall was excluded from the analysis.
Clinical outcomes
Twenty-two patients were evaluable for response. There were no
objective responses by RECIST criteria. Stable disease for 42
cycles was achieved in 18 patients (82%), and 6 patients (27%)
completed all 6 cycles of CYT997 prescribed by the clinical trial
protocol. Most notable were two study participants (patients 21
and 22) who had symptomatic progressive disease prior to study
entry. Both remained in ongoing stable disease beyond 6 cycles
of study treatment and each received an additional 2 cycles of
CYT997 off study, before developing progressive disease. Patient
21 (mesothelioma) received 152mgm
 2 in cycles 1 and 2, and
202mgm
 2 in cycles 3–8. Patient 22 (tracheal adenocarcinoma)
received 202mgm
 2 in all cycles. There was no correlation
between the duration of stable disease and the degree of reduction
in K
trans following CYT997 administration for the entire group of
evaluable patients. However, patient 21 and another patient who
achieved stable disease for 6 cycles (patient 26, ovarian carcinoma)
both had significant post-treatment falls in K
trans (Table 4;
Figure 3).
DISCUSSION
We describe results of the first-in-human clinical trial of the
cytotoxic and VDA CYT997. As shown in Table 2, CYT997 was well
tolerated when given as a 24-h i.v. infusion every 3 weeks at doses
up to and including 202mgm
 2. Grade 3 and 4 toxicities were
observed at higher dose levels, including prolonged QTc interval,
transient uniocular visual loss and dyspnea with hypoxia.
However, all CYT997 toxicities were reversible without sequelae.
The maximum QTc interval observed in the current study was
518ms, and no ventricular tachyarrhythmias were associated with
QTc prolongation in any patient. Dose-related QTc-interval
prolongation has been reported with other VDA (Cooney et al,
2004; McKeage et al, 2006). It is notable that the episode of grade
3–4 dyspnea and hypoxia observed in our study occurred in a
patient with a history of thoracic radiation therapy. Furthermore,
fatal bowel toxicity was reported in a trial of combretastatin A4
phosphate in a patient with previous abdominal radiation (Rustin
et al, 2003). It is therefore possible that ionising radiation may
sensitise the microvasculature of normal tissues to VDA toxicity.
Although the 358mgm
 2 dose level was determined as the MTD in
our study, the dose level below (269mgm
 2) was considered too
toxic to be the recommended dose for phase II studies. One patient
at 269mgm
 2 developed a DLT (QTc-interval prolongation), and
another patient at this dose level experienced a grade 4 visual
disturbance in cycle 2. The next dose level down (202mgm
 2)
might have been explored as a potential single-agent phase II dose.
However, we decided against this as CYT997 will likely be
evaluated further in combination with other anti-cancer drugs,
rather than as a single agent. Trials of such combinations will use
Table 4 DCE-MRI evaluation of tumour vasculature
Baseline Post-treatment
Patient no. Tumour type CYT997 dose (mgm
 2) First Second 26h 6 days
18 Renal cell 65 0.0065 0.0074 0.0062 0.0040
19 Renal cell 86 0.0093 0.0093 0.0108 0.0109
20 NSCLC 114 0.0133 0.0147 0.0153 0.0083
21 Mesothelioma 152 0.0068 0.0057 0.0062 0.0047
22 Tracheal 202 0.0042 0.0060 0.0065 0.0061
24 Mesothelioma 269 0.0083 0.0082 0.0080 0.0081
25 Prostate 269 0.0101 0.0090 0.0064 0.0099
26 Ovarian 269 0.0074 0.0080 0.0088 0.0050
27 Breast 269 0.0030 0.0033 0.0034 0.0030
29 Mesothelioma 358 0.0050 0.0054 0.0057 0.0052
30 Leiomyosarcoma 358 0.0073 0.0073 0.0089 0.0094
Abbreviations: DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; NSCLC¼non-small cell lung cancer. Whole-tumour median K
trans values are shown for the
first and second baseline DCE-MRI scans and the two post-treatment scans (26h and 6 days after starting the first CYT997 infusion) in 11 patients with evaluable data. Post-
treatment median K
trans values are in bold if more than five deciles in the corresponding histogram analysis of K
trans revealed statistically significant changes in the same direction as
the change in the median value (see text and Figure 3).
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escalation strategy to establish the recommended dose.
Pharmacokinetic studies revealed that Css (equivalent to Cmax)
and AUC0 t were proportion to CYT997 dose (Table 3; Figure 1).
In preclinical investigations, the IC50 of CYT997 in diverse cancer
cell lines was in the range 10–100nM (Burns et al, 2009a). Doses at
and above 65mgm
 2 in the current trial achieved plasma
concentrations at steady state of 4100nM and for the three dose
levels immediately below 269mgm
 2 the Css ranged from 253 to
354nM. Therefore, well-tolerated doses of CYT997 resulted in
steady-state plasma levels that were up to 3.5 times higher than the
IC50 of the most resistant cell line tested and up to 35 times higher
than the IC50 of the most sensitive cell line.
Von Willebrand factor levels in plasma were assayed as a PD
indicator of endothelial cell injury following CYT997 treatment.
Levels significantly increased in patients dosed at 202mgm
 2 and
above (Figure 2A), which is consistent with dose-dependent
CYT997-induced vascular disruption and potentially with targeting
of tumour vasculature. However, it is noteworthy that all but one
of the patients showing a significant rise in plasma vWF received
*
* *
* *
*
*
*
*
* *
* *
* *
* *
* *
* *
*
*
*
*
*
*
*
*
*
*
*
*
0.02
0.002
0.000
–0.002
–0.004
–0.006
–0.008
0.002
0.000
–0.002
–0.004
–0.006
–0.008
–0.010
–0.012
–0.014
–0.020
0
Figure 3 Tumour K
trans maps derived from DCE-MRI scans of patients 20 (A, C) and 26 (B, D). Patient 20 received 114mgm
 2 of CYT997 and the
lesion shown is a liver metastasis of non-small cell lung cancer. Patient 26 received 269mgm
 2 and images show a pelvic nodal metastasis of ovarian
carcinoma. Results at baseline (A, B) and 6 days following CYT997 administration (C, D) are shown. Maps are colour coded, and the scale (shown at right)
extends from a maximum K
trans of 0.02min
 1 (yellow end) to zero (blue end). Histograms indicating the mean change in K
trans for each decile of voxels at
6 days following CYT997 treatment are also shown for patients 20 and 26 (E and F, respectively). The bars are arranged so that the decile with the lowest
K
trans values at baseline is on the left of the histogram and the decile with the highest is on the right. Negative values indicate a fall in K
trans after study drug,
compared with baseline. Asterisks indicate statistical significance: *Po0.05, **Po0.0002.
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Figure 4 Correlation between the whole-tumour median K
trans value at
baseline and the maximum decrease in whole-tumour median K
trans
observed following CYT997 treatment. Only data from patients with a fall
in median K
trans at one or both post-treatment time points are shown.
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sdoses X269mgm
 2. These dose levels were associated with grade
3–4 cardiovascular toxicities in some patients and therefore injury
to normal endothelium is another potential source of the increased
plasma vWF. It is not possible to distinguish between these
possibilities based on our data. We also assayed CEC as an
alternative biomarker of vascular disruption. Only one patient
(who was dosed at the MTD) showed an increase. The significance
of this finding is uncertain, but CEC levels do not appear to be a
useful indicator of CYT997-induced vascular disruption.
Caspase-cleaved CK-18 significantly increased in plasma after
CYT997 treatment and the threshold dose for this effect may have
been as low as 86mgm
 2 (Figure 2B). These results indicate that
apoptosis was triggered in CK-18 expressing cells and are consis-
tent with an anti-tumour effect of CYT997. Clearly, however, they
could also reflect subclinical toxicity to normal epithelial tissues.
DCE-MRI scans evaluate perfusion and endothelial permeability
in tumour microvasculature and therefore complement plasma PD
biomarkers by providing both anatomical and physiological
information. We observed changes in serial DCE-MRI scans that
were consistent with significant CYT997-induced reductions in
tumour perfusion in 5 out of 11 evaluable patients (Table 4;
Figure 3). Moreover, two additional patients showed a significant
increase in tumour K
trans. The biology underlying these latter
changes is not fully understood, but could involve increases in
microvascular permeability because of lesser degrees of vascular
disruption by CYT997 (Seshadri et al, 2007). The timing of post-
treatment DCE-MRI scans is likely to be critical to an optimal
assessment of VDA activity. We performed scans at 26h and 6 days
from starting the CYT997 infusion and therefore even major effects
on K
trans occurring between these time points may have been
missed. Nonetheless, the available DCE-MRI observations suggest
that CYT997 possesses significant VDA activity.
The threshold dose for induction of vascular disruptive effects
by CYT997 has not been defined, as significant K
trans changes were
observed at the lowest dose level for which evaluable DCE-MRI
data were available (65mgm
 2). In addition, no convincing dose–
response relationship was evident as doses increased above this
level. CYT997 therefore induced changes consistent with vascular
disruption at doses well below its MTD, which has also been
reported for other VDA (McKeage et al, 2006). The extent to which
CYT997 affected tumour microvasculature was, however, related to
the median K
trans of the tumour at baseline (Figure 4). This
suggests that tumours with more extensive and/or leaky neovas-
culature were more susceptible to vascular disruption by this
agent. Moreover, areas within an individual tumour that possessed
the highest K
trans values at baseline were subject to the greatest
change in blood flow or permeability. CYT997 may therefore be
most effective as a VDA against malignancies with an extensive
abnormal vasculature. It is notable that combretastatin A4
phosphate also triggered greater changes in K
trans in tumours with
higher baseline K
trans levels and appeared to have particular
activity in thyroid tumours, which are often highly vascular
(Dowlati et al, 2002; Stevenson et al, 2003).
In summary, CYT997 administration was associated with
changes in plasma and imaging biomarkers that were consistent
with vascular disruption in tumours. These changes were observed
in some patients at well-tolerated doses. Our results therefore
support the further clinical evaluation of CYT997, which, based on
clinical experience with other vascular-targeting agents, might
optimally be performed in combination with other anti-cancer
therapeutics.
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